This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LifeMD, Inc. (LFMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
LifeMD (LFMD) delivered earnings and revenue surprises of -40% and 0.26%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -23.73% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Company News for Sep 20, 2024
by Zacks Equity Research
Companies In The News Are: PGNY, EWTX, FDS, SCS.
Do Options Traders Know Something About Progyny (PGNY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Progyny (PGNY) stock based on the movements in the options market lately.
Progyny (PGNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Progyny (PGNY) Beats Q2 Earnings Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 19.44% and 1.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Embecta Corp. (EMBC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Embecta Corp. (EMBC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enhabit (EHAB) Beats Q1 Earnings Estimates
by Zacks Equity Research
Enhabit (EHAB) delivered earnings and revenue surprises of 40% and 2.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 51.47% and 25.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to Decline
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Progyny (PGNY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Buy Stocks for October 30th
by Zacks Equity Research
CVEO, FBP, EIG, MNTX and PGNY have been added to the Zacks Rank #1 (Strong Buy) List on October 30, 2023.
New Strong Buy Stocks for October 17th
by Zacks Equity Research
MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
Humana (HUM) Boosts Healthcare Choices for MA Members in Denver
by Zacks Equity Research
Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
by Indrajit Bandyopadhyay
Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.
3 Reasons Growth Investors Will Love Progyny (PGNY)
by Zacks Equity Research
Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Acadia Healthcare (ACHC) Up 11% in 3 Months: More Room to Run?
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on an expansive healthcare portfolio, which in turn, boosts its patient volumes.
Here is Why Growth Investors Should Buy Progyny (PGNY) Now
by Zacks Equity Research
Progyny (PGNY) could produce exceptional returns because of its solid growth attributes.
Progyny (PGNY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compared to Estimates, Progyny (PGNY) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Progyny (PGNY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Progyny (PGNY) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 50% and 6.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
by Zacks Equity Research
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MD vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MD vs. PGNY: Which Stock Is the Better Value Option?